Status:
COMPLETED
Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome
Lead Sponsor:
Seoul National University Hospital
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18-80 years
Brief Summary
In Myelodysplastic syndrome, epigenetic treatments such as Azacitidine and Decitabine have been highlighted in phase 3 studies. However, as the 1st line treatment, it has not been evaluated the head t...
Detailed Description
Among 300 MDS patient, 200 of them have been taking Azacitidine and 100 of them have been taking Decitabine. Medical chart of these patients will be reviewed to assess the efficacy and safety between ...
Eligibility Criteria
Inclusion
- Confirmed MDS by bone marrow examination
- Receiving azacitidine and decitabine as a first line chemotherapy
- Adequate hepatic, cardiac, and renal function
Exclusion
- Previously treated with another anti-cancer therapy due to MDS
- Not available for clinical information
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01409070
Start Date
January 1 2011
End Date
December 1 2011
Last Update
October 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SNUH
Seoul, South Korea